Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.76 |
| ▸ | PGR | P06401 | 4/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | PKLR | P30613 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29031235 | 0.84 | PGR (0.85) | PLAUPGRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL28396503 | 0.84 | PGR (0.77) | PLAUPGRATMSMN1; SMN2MEN1 | |
| SCHEMBL29549847 | 0.84 | PGR (0.77) | PLAUPGRATMSMN1; SMN2MEN1 | |
| SCHEMBL20021987 | 0.84 | PGR (0.77) | PLAUPGRATMSMN1; SMN2MEN1 | |
| SCHEMBL790294 | 0.84 | GAA (0.86) | PLAUPGRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4662975 | 0.82 | PGR (0.82) | PLAUPGRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL812663 | 0.82 | PGR (0.82) | PLAUPGRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27790749 | 0.82 | ATM (0.73) | PLAUPGRATMSMN1; SMN2MEN1 | |
| SCHEMBL8279501 | 0.82 | PLAU (0.65) | PLAUPGRATMSMN1; SMN2MEN1 | |
| SCHEMBL808105 | 0.81 | ATM (0.72) | PLAUPGRATMSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | claimed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | claimed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | claimed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | PLAU 4325/4885PGR 4624/4885ATM 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.